Added 20th June 2016

With an astonishing one million new articles being published every year, the wealth of knowledge now available to researchers is beginning to look more like a burden than a blessing. ...

Added 31st May 2016

For the successful discovery and eventual launch of drugs, researchers need to use all of the available information. However, traditional literature searches of full-text articles are laborious and limiting research ...

Added 31st May 2016

Since the turn of the century, the pharmaceutical industry has seen dramatic changes, including dwindling drug pipelines, looming patent expirations and rising costs. The improved access to high-quality data and ...

Added 31st May 2016

Advances in technology have enabled pharmaceutical companies to move toward more accurate methods in preclinical drug safety work. In vitro and in vivo models, which have often fallen short as ...

Added 31st May 2016

Too many drugs still cause adverse events after reaching clinical trials, despite all the efforts to eliminate unsafe candidates early. This late-stage attrition remains one of the greatest—and most costly—challenges ...

Added 31st May 2016

Finding disease-specific drug targets is becoming more straightforward thanks to the development of text-mining technology. The advances in informatics that allow researchers to search vast virtual libraries have made it ...

Added 31st May 2016

The scope of what pharmacovigilance leaders must consider has greatly increased as regulatory agencies worldwide have broadened their expectations from pharmaceutical companies. The pharmacovigilance department must know about activities beyond ...

Added 31st May 2016

This white paper outlines the practical steps that pharmacovigilance leaders should take in order to achieve and maintain global oversight of their pharmacovigilance process. This is especially important in the ...

Added 31st May 2016

The role of in silico profiling in the drug candidate selection process is growing. Clinical outcome predictions are proving increasingly accurate thanks to both the available higher-quality data and the ...

Added 31st May 2016

Understanding diseases at a molecular level is essential to the accurate identification of drug targets and the discovery of successful drug candidates. To predict a drug’s impact, researchers must have ...

Added 30th May 2016

Addressing unanticipated problems with a drug candidate can be very expensive, especially if the candidate reaches clinical trials before the problem is discovered. The solution is to identify all potential ...

Added 30th May 2016

Lead optimization means the identification of new molecular entities and refinement of their structure to improve potency and pharmacokinetics while reducing off-target effects. Traditionally involving in vitro and in vivo ...

Added 10th March 2016

Life sciences companies are spending more on R&D but are earning less for their efforts. However, dealing with more data does not have to mean reduced productivity. Discover why companies ...

Added 19th January 2016

This white paper looks at how small steps, such as greater data sharing and extending data searches beyond standard literature searches, can bring about huge improvements to pre-clinical R&D productivity. ...

Added 22nd December 2015

QSAR modeling is a powerful tool in the assessment of new chemical entities. Using the example of ErB1 kinase, the dysfunction of which has been implicated in diseases such as ...